Shaun DeJarnette

A risk-based approach to optimize autologous hematopoietic stem cell (HSC) collection with the use of plerixafor

Sunil Abhyankar, Shaun DeJarnette, Omar S. Aljitawi et al. · Bone Marrow Transplantation · 2011 · 88 citations

Medicine, Hematology, Cell Therapy +13

Impact of SARS-CoV-2 in Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Recipients

Muhammad Umair Mushtaq, Moazzam Shahzad, Sibgha Gull Chaudhary et al. · Transplantation and Cellular Therapy · 2021 · 56 citations · Full text

Life Sciences, Immunology, Infectious Diseases +10

Impact of Extraosseous Extramedullary Disease on Outcomes of Patients with Relapsed-Refractory Multiple Myeloma receiving Standard-of-Care Chimeric Antigen Receptor T-Cell Therapy

Danai Dima, Al‐Ola Abdallah, James A. Davis et al. · Blood Cancer Journal · 2024 · 41 citations · Full text

Medicine, Hematology, Oncology +16

Impact of Frailty on Outcomes after Chimeric Antigen Receptor T Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma

James A. Davis, Danai Dima, Nausheen Ahmed et al. · Transplantation and Cellular Therapy · 2023 · 36 citations

Medicine, Immunology, Oncology +12

Efficacy and safety of idecabtagene vicleucel in patients with relapsed–refractory multiple myeloma not meeting the <scp>KarMMa</scp>‐1 trial eligibility criteria: A real‐world multicentre study

Danai Dima, Aliya Rashid, James A. Davis et al. · British Journal of Haematology · 2024 · 24 citations · Full text

Medicine, Oncology, Pharmacotherapy +17